Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 10.66 as of 2026-10-06T15:47:45.937Z.
Consensus retrieved: 2026-10-06T15:02:41.216Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:47:45.937Z.
Quote observation: 2026-10-06T15:45:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 76f5337cecebf7e78a01ddb3a752de5f83f3a303fd6608f88032b7c8ddb3b53c
Forward PE Ratio (10.66) = Dated Quote Price ($37.30) / Consensus Forward EPS ($3.50)
FORWARD PE RATIO
10.66
SECTOR MEDIAN · HEALTHCARE
19.77
median of 171 covered companies
CURRENT VS SECTOR MEDIAN
-46.08%
vs the sector median at left
Phibro Animal Health Corporation
Market Cap
$1.51B
Forward PE Ratio
10.66
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Phibro Animal Health Corporation (PAHC) | $1.51B | 10.66 |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.51B | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.52B | 50.96 |
| GH Research PLC (GHRS)vs › | $1.50B | N/A |
| Certara, Inc. (CERT)vs › | $1.49B | 28.14 |
| Innoviva, Inc. (INVA)vs › | $1.54B | 8.63 |
| uniQure N.V. (QURE)vs › | $1.54B | N/A |
| Nutex Health, Inc. (NUTX)vs › | $1.55B | 8.08 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.47B | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.47B | N/A |
Trailing P/E
15.3
reported TTM EPS
Forward P/E
10.7
consensus EPS · fiscal year ending 2027-06-30
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $3.50 implies +43.4% EPS growth vs the reported trailing $2.44.
At the dated quote price of $37.30, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-06-30 | $3.50 | $3.46 – $3.53 | 3 | 10.7x |
| 2028-06-30 | $3.84 | $3.68 – $4.07 | 3 | 9.7x |
| 2029-06-30 | $4.11 | $4.09 – $4.13 | 1 | 9.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
